trending Market Intelligence /marketintelligence/en/news-insights/trending/q1xPW5dvWuS_s10jeJgpDQ2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Biopharma firm Transcenta raises US$100M in financing round

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Biopharma firm Transcenta raises US$100M in financing round

Chinese biopharmaceutical firm Transcenta Holding Ltd. raised US$100 million in a series B+ financing round.

New investors CR-CP Life Sciences Fund, Fortune Venture Capital Co. Ltd., Epiphron Capital, CCT China Merchant Buyout Fund, and China Equity Group participated in the round alongside existing shareholders Lilly Asia Ventures, Temasek, Hillhouse Capital, Teng Yue Partners LP, Sequoia Capital China, and Arch Venture Partners LP.

Transcenta was formed in January 2019 following the merger between MabSpace Biosciences in Hong Kong and HJB, which has sites in China and the U.S.